Ex Vivo Expansion of Cord Blood

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2009 Oct 6

PMID 19802023

Citations 39

Authors

S S Kelly

C B S Sola

M de Lima

E Shpall

Affiliations

Soon will be listed here.

Abstract

A marked increase in the utilization of umbilical cord blood (UCB) transplantation has been observed in recent years; however, the use of UCB as a hematopoietic stem cell (HSC) source is limited primarily by the number of progenitor cells contained in the graft. Graft failure, delayed engraftment and profound delay in immune reconstitution lead to significant morbidity and mortality in adults. The lack of cells available for post transplant therapies, such as donor lymphocyte infusions, has also been considered to be a disadvantage of UCB. To improve outcomes and extend applicability of UCB transplantation, one potential solution is ex vivo expansion of UCB. Investigators have used several methods, including liquid suspension culture with various cytokines and expansion factors, co-culture with stromal elements and continuous perfusion systems. Techniques combining ex vivo expanded and unmanipulated UCB are being explored to optimize the initial engraftment kinetics as well as the long-term durability. The optimal expansion conditions are still not known; however, recent studies suggest that expanded UCB is safe. It is hoped that by ex vivo expansion of UCB, a resulting decrease in the morbidity and mortality of UCB transplantation will be observed, and that the availability of additional cells may allow adoptive immunotherapy or gene transfer therapies in the UCB setting.

Citing Articles

Alginate-gelatin hydrogel promotes the neurogenic differentiation potential of bone marrow CD117 hematopoietic stem cells.

Peng J Regen Ther. 2024; 26:1030-1036.

PMID: 39569341 PMC: 11576937. DOI: 10.1016/j.reth.2024.10.009.

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S Transplant Cell Ther. 2023; 29(5):338.e1-338.e6.

PMID: 36775201 PMC: 10149622. DOI: 10.1016/j.jtct.2023.01.031.

Tailored Cytokine Optimization for Culture Platforms Targeting the Expansion of Human Hematopoietic Stem/Progenitor Cells.

Branco A, Bucar S, Moura-Sampaio J, Lilaia C, Cabral J, Fernandes-Platzgummer A Front Bioeng Biotechnol. 2020; 8:573282.

PMID: 33330414 PMC: 7729524. DOI: 10.3389/fbioe.2020.573282.

Safety and efficacy of ex vivo expanded CD34 stem cells in murine and primate models.

Zhang Y, Shen B, Guan X, Qin M, Ren Z, Ma Y Stem Cell Res Ther. 2019; 10(1):173.

PMID: 31196160 PMC: 6567473. DOI: 10.1186/s13287-019-1275-0.

Evaluation of hematopoietic stem cell expansion in the presence of garcinol.

Habibi A, Soleimani M, Atashi A, AkhavanRahnama M, Anbarlou A, Ajami M Avicenna J Phytomed. 2018; 8(4):350-357.

PMID: 30377593 PMC: 6204147.

References

Gammaitoni L, Weisel K, Gunetti M, Wu K, Bruno S, Pinelli S . Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood. 2004; 103(12):4440-8. DOI: 10.1182/blood-2003-09-3079. View

Yamaguchi M, Hirayama F, Kanai M, Sato N, Fukazawa K, Yamashita K . Serum-free coculture system for ex vivo expansion of human cord blood primitive progenitors and SCID mouse-reconstituting cells using human bone marrow primary stromal cells. Exp Hematol. 2001; 29(2):174-82. DOI: 10.1016/s0301-472x(00)00653-6. View

Gotherstrom C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K . Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 2004; 190(1):239-45. DOI: 10.1016/j.ajog.2003.07.022. View

Moore M, Sheridan A, ALLEN T, Dexter T . Prolonged hematopoiesis in a primate bone marrow culture system: characteristics of stem cell production and the hematopoietic microenvironment. Blood. 1979; 54(4):775-93. View

Migliaccio A, Adamson J, Stevens C, Dobrila N, Carrier C, Rubinstein P . Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood. 2000; 96(8):2717-22. View

In t Anker P, Noort W, Kruisselbrink A, Scherjon S, Beekhuizen W, Willemze R . Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol. 2003; 31(10):881-9. DOI: 10.1016/s0301-472x(03)00202-9. View

Broxmeyer H, Gluckman E, Auerbach A, Douglas G, Friedman H, Cooper S . Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning. 1990; 8 Suppl 1:76-89; discussion 89-91. DOI: 10.1002/stem.5530080708. View

Mohamed A, Ibrahim A, El-Masry M, Mansour I, Khroshied M, Gouda H . Ex vivo expansion of stem cells: defining optimum conditions using various cytokines. Lab Hematol. 2006; 12(2):86-93. DOI: 10.1532/LH96.05033. View

Thomson B, Robertson K, Gowan D, Heilman D, Broxmeyer H, Emanuel D . Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood. 2000; 96(8):2703-11. View

10.

Young J, Wu S, Hansteen G, Du C, Sambucetti L, Remiszewski S . Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. Cytotherapy. 2005; 6(4):328-36. DOI: 10.1080/14653240410004899. View

11.

Le Blanc K . Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003; 5(6):485-9. DOI: 10.1080/14653240310003611. View

12.

Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B . Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol. 2004; 32(7):657-64. DOI: 10.1016/j.exphem.2004.04.001. View

13.

Kadereit S, Deeds L, Haynesworth S, Koc O, Kozik M, Szekely E . Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer. Stem Cells. 2002; 20(6):573-82. DOI: 10.1634/stemcells.20-6-573. View

14.

Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M . Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol. 2004; 60(3):307-15. DOI: 10.1111/j.0300-9475.2004.01483.x. View

15.

Fuchs E, Tumbar T, Guasch G . Socializing with the neighbors: stem cells and their niche. Cell. 2004; 116(6):769-78. DOI: 10.1016/s0092-8674(04)00255-7. View

16.

Liu Y, Liu T, Fan X, Ma X, Cui Z . Ex vivo expansion of hematopoietic stem cells derived from umbilical cord blood in rotating wall vessel. J Biotechnol. 2006; 124(3):592-601. DOI: 10.1016/j.jbiotec.2006.01.020. View

17.

Lewis I, Almeida-Porada G, Du J, Lemischka I, Moore K, Zanjani E . Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system. Blood. 2001; 97(11):3441-9. DOI: 10.1182/blood.v97.11.3441. View

18.

Boissel L, Tuncer H, Betancur M, Wolfberg A, Klingemann H . Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant. 2008; 14(9):1031-1038. DOI: 10.1016/j.bbmt.2008.06.016. View

19.

Filip S, Vavrova J, Vokurkova D, Blaha M, Vanasek J . Myeloid differentiation and maturation of SCF+IL-3+IL-11 expanded AC133+/CD34+ cells selected from high-risk breast cancer patients. Neoplasma. 2000; 47(2):73-80. View

20.

Murray L, Young J, Osborne L, Luens K, Scollay R, Hill B . Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. Exp Hematol. 1999; 27(6):1019-28. DOI: 10.1016/s0301-472x(99)00031-4. View